Title
Identification of a third pathway for arachidonic acid mobilization and prostaglandin production in activated P388D1 macrophage-like cells.

Permalink
https://escholarship.org/uc/item/7kh273mr

Journal
The Journal of biological chemistry, 275(29)

ISSN
0021-9258

Authors
Balsinde, J
Balboa, MA
Dennis, EA

Publication Date
2000-07-01

DOI
10.1074/jbc.m910163199

Peer reviewed
Identification of a Third Pathway for Arachidonic Acid Mobilization and Prostaglandin Production in Activated P388D1 Macrophage-like Cells

Jesús Balsinde‡, María A. Balboa, and Edward A. Dennis§

From the Department of Chemistry and Biochemistry, Revelle College and School of Medicine, University of California at San Diego, La Jolla, California 92093-0601

Previous studies have demonstrated that P388D1 macrophages are able to mobilize arachidonic acid (AA) and synthesize prostaglandins in two temporally distinct phases. The first phase is triggered by platelet-activating factor within minutes, but needs the cells to be previously exposed to bacterial lipopolysaccharide (LPS) for periods up to 1 h. It is thus a primed immediate phase. The second, delayed phase occurs in response to LPS alone over long incubation periods spanning several hours. Strikingly, the effector enzymes involved in both of these phases are the same, namely the cytosolic group IV phospholipase A2 (cPLA2), the secretory group V phospholipase A2, and cyclooxygenase-2, although the regulatory mechanisms differ. Here we report that P388D1 macrophages mobilize AA and produce prostaglandins in response to zymosan particles in a manner that is clearly different from the two described above. Zymosan triggers an immediate AA mobilization response from the macrophages that neither involves the group V phospholipase A2 nor requires the cells to be primed by LPS. The group VI Ca2+-independent phospholipase A2 is also not involved. Zymosan appears to signal exclusively through activation of the cPLA2, which is coupled to the cyclooxygenase-2. These results define a secretory PLA2-independent pathway for AA mobilization in the P388D1 macrophages, and demonstrate that, under certain experimental settings, stimulation of the cPLA2 is sufficient to generate a prostaglandin biosynthetic response in the P388D1 macrophages.

Phospholipase A2 (PLA2) enzymes play key roles in a variety of cellular processes by generating a number of bioactive mediators. PLA2-mediated hydrolysis of phospholipids results in the release of arachidonic (AA) and lysophospholipids, both of which may possess biological activity or serve as substrates for the generation of other bioactive lipid mediators such as the eicosanoids or platelet-activating factor (PAF) (1, 2).

In major eicosanoid-producing immunoinflammatory cells such as macrophages and mast cells, prostaglandin production usually occurs in two phases (1, 2). The first phase takes place in minutes and is strikingly characterized by its dependence on Ca2+ mobilization from internal stores; whereas, the second, delayed phase, spanning several hours, takes place in the absence of Ca2+ elevations (2). Substantial evidence suggests that specific coupling between certain PLA2 and cyclooxygenase (COX) forms accounts for the differential regulation of the immediate and delayed responses (3–14). Thus, depending on whether group IV cPLA2 or sPLA2 (group IIA or group V) is the provider of free AA, either COX-1 or COX-2 would be responsible for prostaglandin production. Which PLA2 form couples to which COX isoform appears also to depend critically on cell type.

We have shown that the rapid, PAF receptor-mediated phase of PGE2 production in lipopolysaccharide (LPS)-primed P388D1 macrophages involves group V sPLA2 coupling to COX-2 (4). It is important to emphasize here that this response to PAF will not occur if the cells have not been first exposed to bacterial LPS for 1 h (15, 16). Thus the P388D1 cell response to PAF is not, strictly speaking, an immediate response but rather a primed immediate one.

Interestingly, we have recently discovered that group V sPLA2 also couples to COX-2 for the delayed PGE2 biosynthetic response of P388D1 macrophages exposed to LPS alone (5, 17). Under those conditions, expression of both group V sPLA2 and COX-2 is markedly induced and correlates with ongoing AA release and prostaglandin biosynthesis, respectively (5), indicating that the AA produced by group V sPLA2 is used by COX-2 to produce PGE2. Importantly, expression of both group V sPLA2 and COX-2 can be abolished by pretreating the cells with the cPLA2 inhibitor methyl arachidonyl fluorophosphonate, implying that a functionally active cPLA2 is essential for the delayed PGE2 response to occur (5, 17).

In the current study we have uncovered a third pathway for AA mobilization and PGE2 production in activated P388D1 macrophages that appears not to require the group V sPLA2. We show here that exposure of the cells to zymosan particles triggers the immediate release of both AA and PGE2 in a process that depends only on cPLA2 and COX-2. Thus in P388D1 macrophages there are at least three different phases for AA release: an immediate phase (zymosan), which does not require the participation of the sPLA2, a primed immediate phase (LPS/PAF), which does require the sPLA2, and a delayed phase (LPS), which also requires the sPLA2. All of the three phases, however, require the cPLA2.
Experimental Procedures

Materials—Isco's modified Dulbecco's medium (endotoxin <0.05 ng/ml) was from Whittaker Bioproducts (Walkersville, MD). Fetal bovine serum was from Hyclone Labs. (Logan, UT). Nonsessential amino acids were from Irvine Scientific (Santa Ana, CA). [5,6,8,9,11,12,14,15-3H]Arachidonic acid (specific activity 100 Ci/mmol) was from New England Nuclear (Boston, MA). PAF, LPS (Escherichia coli 0111:B4), and yeast-derived zymosan were from Sigma. Methyl arachidonoyl fluorophosphate (MAFP), bromoel olanole lactone (BEL), and NS-398 were from Biomol (Plymouth Meeting, PA). The sPLA2 inhibitor LY311727 was generously provided by Dr. Edward Mihelich (Lilly Research Labs, Indianapolis, IN). iPLA2 antiserum was generously provided by Dr. Simon Jones (Genetics Institute, Cambridge, MA). Human recombinant group V sPLA2 was produced in our laboratory utilizing the Pichia pastoris expression system (17).

Cell Culture and Labeling Conditions—P388D1 cells (MAB clone) (5, 17) were maintained at 37 °C in a humidified atmosphere at 90% air and 10% CO2 in Isco's modified Dulbecco's medium supplemented with 10% fetal bovine serum, 2 m M glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, and nonessential amino acids. P388D1 cells were plated at 106/well, allowed to adhere overnight, and used for experimentation. A 5 mg/ml solution of PAF was added to cells 30 min before stimulation. The cells were placed in serum-free medium for 30 min before stimulation. Afterward, the supernatants were removed and cleared of detached cells by centrifugation, and [3H]AA was quantitated using a specific radioimmunoassay (PersPective Biosystems, Framingham, MA). For [3H]AA release experiments, cells labeled with [3H]AA were used, and the incubations were performed in the presence of 0.3 mg/ml bovine serum albumin. All experiments were conducted in serum-free Isco's modified Dulbecco's medium. When required, radio-labeling of the P388D1 cells with [3H]AA was achieved by including 0.5 μCi/ml [3H]AA during the overnight adherence period (20 h). Labeled AA that had not been incorporated into cellular lipids was removed by washing the cells four times with serum-free medium containing 1 mg/ml albumin.

Measurement of PGE2 Production and of Extracellular [3H]AA Release—The cells were placed in serum-free medium for 30 min before the addition of zymosan for different periods of time. Afterward, the supernatants were removed and cleared of detached cells by centrifugation, and PGE2 was quantitated using a specific radioimmunoassay (15, 25).

Preparation of Zymosan—Zymosan was prepared exactly as described (18). Briefly, zymosan particles were suspended in phosphate-buffered saline, boiled for 60 min, and washed three times. The final pellet was resuspended in phosphate-buffered saline at 20 mg/ml and stored frozen. Zymosan aliquots were diluted in serum-free medium and sonicated before addition to the cells. No PLA2 activity was detected in the zymosan batches used in this study, as assessed by in vitro assays (19).

iPLA2 Antisense Inhibition Studies—A 20-base-long antisense complementary to nucleotides 59–78 in the murine group VI iPLA2 sequence (20) was utilized (ASGV1-18, 5'-CTCC CAT CCC GAA TGA TGG GT-3'). As a control, a sense complement of ASGV1-18 was used (SGV1-18, 5'- ACC CAT TCC GGG TGA AGG AG-3'). Both ASGV1-18 and SGV1-18 contained phosphorothioate linkages to limit degradation. We have previously described a procedure of transfection that involves long incubation periods of the cells with the oligonucleotides (21). In the current study, we have employed the procedure recently described by Akiba et al. (22) in which the oligonucleotides are presented to the cells in a complex with a lipophilic carrier. The antisense and sense oligonucleotides were mixed with LipofectAMINE, and complexes were allowed to form at room temperature for 10–15 min. The complexes were then added to the cells, and the incubations were allowed to proceed for 24 h under standard cell culture conditions. The final concentrations of oligonucleotide and LipofectAMINE in the incubation medium were 0.5 μM and 10 μg/ml, respectively. Oligonucleotide treatment and culture conditions were not toxic for the cells as assessed by the Trypan blue dye exclusion assay and by quantitating adherent cell protein.

Immunoblot Analysis of iPLA2—The cells were lysed in a buffer consisting of 150 mM NaCl, 20 mM Tris-HCl, 0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 20 μM leupeptin, 20 μM aprotinin, 100 mM sodium vanadate, pH 7.5. The homogenates were centrifuged at 5000 g for 5 min at 4 °C to separate nuclei. Samples (50 μg) were separated by SDS-polyacrylamide gel electrophoresis (10% acrylamide gel) and transferred to Immobilon-P (Millipore). Non-specific binding was blocked by incubating the membranes with a buffer consisting of 5% nonfat milk, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 150 mM NaCl, and 0.1% Triton X-100 for 60 min. Membranes were then incubated with anti-iPLA2 antiserum at a 1:1000 dilution for 30 min and then treated with horseradish peroxidase-conjugated protein A (Amersham Pharmacia Biotech). Bands were detected by enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech).

Measurement of DAG Levels—After the stimulations, the cell supernatants were taken off, and the cell monolayers were scraped with 0.5% Triton X-100. Total lipids were extracted according to the method of Bligh and Dyer (23). Lipids were separated by thin-layer chromatography with n-hexane/diethyl ether/acetic acid (70:30:1, by vol). This system allows a good resolution among phospholipids, monoacylglycerol, DAG, free fatty acids, and triacylglycerol (24). The plates were revealed by exposing them to iodine vapors, and the spot corresponding to DAG was cut out and assayed for radioactivity by liquid scintillation counting.

Data Presentation—Except for the data in Fig. 4, zymosan-stimulated AA release is expressed by subtracting the basal rate in the absence of agonist and inhibitor. These background values were in the range 2000–3000 cpm. Assays were carried out in duplicate or triplicate. Each set of experiments was repeated at least three times with similar results. Unless otherwise indicated, the data presented are from representative experiments.

Results

Zymosan-induced [3H]AA Release in P388D1/MAB Cells—We have recently reported on the use of a P388D1 cell subclone, termed MAB, which manifests considerably higher [3H]AA release responses to LPS and PAF than the ATCC cell batch from which the MAB clone was derived (5). We have repeatedly been unable to detect AA release in response to yeast-derived zymosan from P388D1 cell batches directly obtained from the ATCC (15, 25). Highlighting another striking difference between the MAB cells and their parent ATCC cells, Fig. 1A shows that the MAB cells do respond to yeast-derived zymosan by rapidly releasing [3H]AA to the extracellular medium. The concentration dependence of the effect of zymosan on [3H]AA release is shown in Fig. 1B. Maximal effects were observed at zymosan concentrations between 0.25–0.5 mg/ml. From these data, a zymosan concentration of 0.5 mg/ml was chosen to be employed in all subsequent experiments.

Role of cPLA2 and iPLA2 in Zymosan-stimulated AA Release—Fig. 2 shows that the zymosan-induced AA release was...
Concentration of 25 M. To distinguish whether the inhibition of MAFP on AA release was because of either cPLA2 or iPLA2, we conducted studies with BEL, a compound that manifests a marked selectivity for inhibition of the iPLA2 versus the cPLA2 (3). BEL, at concentrations that we have previously shown to block P388D1 cell iPLA2 in vitro (26), had no significant effect on zymosan-stimulated AA release (Fig. 3A). Failure of BEL to inhibit the AA release was not because of the inhibitor not being able to cross the plasma membrane, because under identical experimental conditions BEL did inhibit zymosan-induced DAG production in a concentration-dependent manner (Fig. 3B). The latter effect most likely reflects the inhibition by BEL of the Mg2+-dependent phosphatidate phosphohydrolase (27). In turn, the absence of an effect of BEL on zymosan-induced AA release indicates that the MAFP effects shown in Fig. 2 are because of inhibition of the cPLA2, not the iPLA2.

To further substantiate the lack of a role for the iPLA2 in zymosan-stimulated AA release, we also examined the effects of an iPLA2 antisense oligonucleotide, which we have previously used to attenuate the levels of immunoreactive iPLA2 in P388D1 cells (21). Using this antisense, we detected a decrease in the immunoreactive iPLA2 protein of about 60%, as judged by Western blot (Fig. 4A). iPLA2-deficient cells, however, did not show any significant reduction of their capacity to release AA to the extracellular medium, either spontaneously or in response to zymosan (Fig. 4B). Collectively, the data of Figs. 3 and 4 strongly suggest that the iPLA2 does not play a significant role in mediating agonist-induced AA mobilization in P388D1 cells.

**sPLA2 Role**—To investigate the involvement of the sPLA2 in zymosan-stimulated AA release, we employed LY311727, a well known sPLA2 inhibitor (1). Treatment of the cells with 25 μM LY311727 had no appreciable effect on the zymosan-stimulated AA release (Fig. 5). We have previously shown that this treatment leads to a marked reduction of the AA release response of the cells to LPS/PAF (3). Identical results were obtained with the use of CMPE (N-derivatized phosphatidylethanolamine covalently linked via the headgroup to carboxymethyl cellulose), another sPLA2 inhibitor that is structurally unrelated to LY311727 (28), and that we have previously shown to strongly inhibit fatty acid release in LPS-activated P388D1 macrophages (29). In keeping with these previous data, CMPE strongly inhibited the LPS/PAF-induced AA release but had no measurable effect on the response to zymosan (data not shown). These results, together with the finding that zymosan did not increase cellular group V sPLA2 mRNA levels for periods of time up to 1 h, strongly suggest that sPLA2 has no role in zymosan-stimulated AA release.

The priming effect of LPS on PAF-induced AA mobilization in P388D1 cells is thought to involve the increased synthesis of group V sPLA2 (4, 30). Interestingly LPS also primed the AA release in response to zymosan (Fig. 5). This effect was found to be inhibited by LY311727, implying the involvement of group V sPLA2 in the priming effect (Fig. 5). Likewise, the addition of exogenous group V sPLA2 to the zymosan-treated cells increased the AA release in a concentration-dependent manner (Fig. 6). Thus, when cellular sPLA2 levels are increased because of the LPS treatment or to the addition of exogenous enzyme, the zymosan response is accordingly increased. Collectively the data indicate that the lack of involvement of sPLA2 in the response triggered by zymosan alone is not because of zymosan suppression of endogenous sPLA2 activity.

**Role of COX-2 in the Zymosan Stimulation of P388D1 Cells**—We have previously observed that in addition to COX-1, P388D1 macrophages constitutively express low levels of COX-2 (4, 17). Therefore it was of interest to examine which of these COX isoforms participates in the prostaglandin response of the cells to zymosan. Neither COX-1 nor COX-2 levels were changed during incubation of the cells for 1 h with zymosan, as assessed by immunoblot. We studied the effect of NS-398, a compound that inhibits COX-2 with an IC50 < 5 μM, whereas COX-1 remains unaffected at concentrations higher than 100 μM (31). Fig. 7 shows complete inhibition of zymosan-induced PGE2 production by NS-398, which indicates that COX-2 is responsible for the response.

---

**Fig. 2.** Effect of MAFP on zymosan-induced [3H]AA release.
The cells were treated with the indicated concentrations of MAFP for 30 min before the addition of zymosan (closed symbols), and the incubations proceeded for 1 h. Open circles denote control incubations, i.e. those that did not receive zymosan.

**Fig. 3.** Effect of BEL on zymosan-induced [3H]AA release (A) and [3H]DAG accumulation (B). The cells were treated with the indicated concentrations of BEL for 30 min before the addition of zymosan (closed symbols), and the incubations proceeded for 1 h. Open circles denote control incubations, i.e. those that did not receive LPS. Afterward, AA release (A) was determined in the supernatants and DAG accumulation (B) was determined in the cell monolayers as described under “Experimental Procedures.”
DISCUSSION

We have recently identified in P388D1 macrophages (MAB clone) the existence of two distinct pathways for AA mobilization and prostaglandin production. The first one, herein referred to as the “primed immediate phase” takes place in minutes and is elicited by the Ca\(^{2+}\)-mobilizing agonist PAF but requires the cells to be exposed first to LPS for 1 h (3, 4, 30, 32). The second pathway, or “delayed phase,” is elicited by LPS for periods of time spanning several hours (4, 5, 33). Interestingly, both pathways utilize the same effectors, namely cPLA\(_2\), sPLA\(_2\), and COX-2, although the molecular mechanisms involved dramatically differ (3, 4, 5, 30, 32, 33). In both of these routes the cPLA\(_2\) appears to behave primarily as an initiator of the response, whereas the sPLA\(_2\) plays an augmentative role by providing most of the AA to be converted to prostaglandins via COX-2.

In the current study we show that zymosan triggers AA mobilization and prostaglandin synthesis in the P388D1 macrophages by a pathway that is clearly different from the ones identified for LPS and PAF. Thus, zymosan elicits an “immediate” AA response whose unique features are that (i) it does not cease after a few minutes but goes on for longer times, (ii) takes place in the absence of LPS priming, and (iii) utilizes only the cPLA\(_2\) to effect the AA release. In common with the response to PAF, however, prostaglandin production in the zymosan-stimulated cells is also mediated by COX-2. Thus, in zymosan-stimulated cells cPLA\(_2\) couples directly to COX-2 for prostaglandin production. This is strikingly different from the situation in the PAF-stimulated cells, where the bulk of the prostaglandins is produced by a sPLA\(_2\)/COX-2 coupling mechanism (4).

Exposure of the P388D1 macrophages to LPS increases group V sPLA\(_2\) levels in a concentration-dependent manner and this appears to constitute a key event of LPS priming (5, 30). We have found here that zymosan does not trigger the increased synthesis of new sPLA\(_2\). However, resting cells still contain appreciable amounts of sPLA\(_2\) (30). Thus it is not easy to envision the reasons for the zymosan not to signal to AA release via recruitment of the endogenous sPLA\(_2\) already present in the cell. We have previously observed that the sPLA\(_2\) pool located on the cell surface appears to be involved in the LPS/PAF-induced AA mobilization and prostaglandin production (19, 30). sPLA\(_2\) levels on the surface of the LPS/PAF-activated

FIG. 4. Effects of an iPLA\(_2\) antisense oligonucleotide on iPLA\(_2\) protein and zymosan-induced AA release. The cells were treated for 24 h with 1 \(\mu\)M antisense (ASGV-18), sense (SGV-18) oligonucleotide, or vehicle (Control). A, effect on iPLA\(_2\) protein. The inset shows the immunoblot from which the densitometry data were obtained. B, effect on zymosan-stimulated AA release. The cells, treated with ASGV-18, SGV-18, or neither as indicated, were incubated without (open bars) or with (gray bars) zymosan for 1 h. Extracellular \(^{3}H\)AA release was quantitated as described under “Experimental Procedures.”

FIG. 5. Effect of LY331727 on AA release. The cells were treated with the indicated concentrations of LY331727 for 30 min before the addition of zymosan (closed circles), LPS for 1 h followed by zymosan (inverted triangles), or neither (open circles) as indicated.

FIG. 6. Effect of exogenous group V sPLA\(_2\) on zymosan-stimulated AA release. The cells were treated without (open circles) or with zymosan (closed circles) in the presence of the indicated concentrations of exogenous group V sPLA\(_2\). Afterward, supernatants were assayed for \(^{3}H\)AA release.

FIG. 7. Effect of NS-398 on PGE\(_2\) production. The cells were treated with the indicated concentrations of NS-398 for 30 min before the addition of zymosan (closed symbols), and the incubations proceeded for 1 h. Open circles denote control incubations, i.e. those that did not receive zymosan.
cells are higher than in resting unstimulated cells (4, 30). This increased sPLA₂ expression can be blocked by actinomycin D (4), indicating the involvement of de novo protein synthesis. We have failed to detect an increase in group V sPLA₂ mRNA levels in cells stimulated by zymosan for periods of time up to 1 h. Thus, a tempting but yet speculative idea to explain the lack of sPLA₂ involvement in the zymosan response would be that the stimulus fails to recruit the constitutive sPLA₂ to the appropriate cell compartment, i.e., the cell surface. Interestingly, a recent report has shown that a majority of the group V sPLA₂ that murine mast cells constitutively express is found intracellularly located during the resting state (34).

P388D₁ macrophages contain a third PLA₂ type, the group VI iPLA₂. By using chemical inhibitors and antisense approaches, we have shown that this enzyme does not seem to participate in the stimulation of AA release by zymosan. In agreement with our data, Akiba et al. (22) recently reported that MAFP strongly inhibits the zymosan-stimulated AA release in P388D₁ cells. Interestingly, Akiba et al. (22) also showed that low BEL concentrations (2 μM) partially decreased the AA release (up to 40%). This finding led the authors to suggest that, in addition to the cPLA₂, the iPLA₂ also involved in the response. At 2 μM, no effect of BEL on DAG levels was detected but an inhibitory effect on the response became evident at 5 μM, which is in agreement with the results of our study. The discrepancy between the data by Akiba et al. (22) and ours regarding BEL effects on AA release probably arises from the fact that Akiba et al. (22) have used a heterogeneous P388D₁ cell population for their studies, whereas we have employed a clone of these cells, termed MAB (5, 17). Closer examination of the results by Akiba et al. (22) reveals that the concentration-response curves for the inhibitory effects of BEL on zymosan-stimulated AA release and endogenous iPLA₂ activity do not correspond (cf. Fig. 2, A and B, in Ref. 22). Maximal effects of BEL on AA release are found at 2 μM, but at this concentration, endogenous iPLA₂ activity is only inhibited by 40%; BEL concentrations higher than 10 μM were found to be required for full iPLA₂ inhibition (22). Thus, the BEL effects on zymosan-induced AA release reported by Akiba et al. (22) are likely not because of inhibition of the iPLA₂ but of another unidentified effector.

Akiba et al. (22) also utilized antisense technology to study the role of iPLA₂ in their system. Surprisingly however, the functional consequences of iPLA₂ antisense depletion were investigated on prostaglandin D₂ production, not on the more direct analysis of AA release (22). A potential problem with this approach is that high BEL concentrations (2 μM) partially decreased endogenous iPLA₂ activity as assessed by immunoblot. We have also found that iPLA₂ depletion by antisense does not result in a decreased capacity of the cells to release AA to the incubation medium in response to zymosan. We previously observed that iPLA₂ depletion by the same antisense oligonucleotide also has no effect on the AA release response induced by LPS/PAF (21).

Our previous studies have suggested that the iPLA₂ serves in a phospholipid remodeling role that involves the generation of lysophospholipid precursors for incorporation of AA into phospholipids (35). Such a housekeeping function for the iPLA₂ was deduced from experiments involving inhibition of iPLA₂ activity with BEL (26, 36) or with an antisense oligonucleotide (21). Importantly, our data have now been confirmed and extended by other laboratories (37–40). Thus the role of iPLA₂ in regulating basal phospholipid deacylation/reacylation reactions appears not to be restricted to the P388D₁ cells but rather may represent a general homeostatic mechanism for the regulation of phospholipid levels. However, a recent study in pancreatic islets failed to detect a role for the iPLA₂ in basal AA incorporation into the phospholipids of these cells (41). It is important to note that, as the authors themselves acknowledge (41), pancreatic islets exhibit some atypical features of AA incorporation in that the basal levels of both esterified AA and lysophosphatidylcholine in these cells are substantially higher than in other tissues (41). Given the high levels and apparently slow turnover of lysophosphatidylcholine in these cells (41), the finding that lysophosphatidylcholine levels do not limit AA incorporation into islet phospholipids does not come as a surprise. Whether the observations with pancreatic islets represent another mechanism for incorporation of AA into phospholipids or merely reflect atypical features of a particular cell type is not yet certain.

In summary, we have described in this work the existence of a third, immediate pathway for AA mobilization and prostaglandin production that operates via activation of the cPLA₂ coupled to COX-2. Neither group V sPLA₂ nor group VI iPLA₂ appear to be involved.

Acknowledgments—We thank Dr. Satoshi Akiba (Kyoto Pharmaceutical University, Japan) for helpful discussions during the course of this work and Dr. Michelle Winsett for reading the manuscript.

Note Added in Proof—While this manuscript was under review, a report appeared (Gijoñ, M. A., Spencer, D. M., Siddiqi, A. R., Bonventre, J. V., and Leslie, C. C. [2000] J. Biol. Chem. 275, 20146–20156) showing that in macrophages obtained from cPLA₂ knock-out mice, zymosan was unable to induce AA release. These results are fully consistent with the data presented in this manuscript and confirm the usefulness of the P388D₁ cells as a model for macrophage activation studies.

REFERENCES

1. Balsinde, J., Balboa, M. A., Insel, P. A., and Dennis, E. A. (1999) Annu. Rev. Pharmacol. Toxicol. 39, 175–189
2. Murakami, M., Nakatani, Y., Atsumi, G., Inoue, K., and Kudo, I. (1997) Crit. Rev. Immunol. 17, 225–283
3. Balsinde, J., and Dennis, E. A. (1999) J. Biol. Chem. 274, 6758–6765
4. Balsinde, J., Balboa, M. A., and Dennis, E. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7951–7956
5. Shinohara, H., Balboa, M. A., Johnson, C. A., Balsinde, J., and Dennis, E. A. (1999) J. Biol. Chem. 274, 12263–12268
6. Murakami, M., Kambe, T., Shimbara, S., and Kudo, I. (1999) J. Biol. Chem. 274, 3105–3115
7. Tada, K., Murakami, M., Kambe, T., and Kudo, I. (1998) J. Immunol. 161, 5098–5105
8. Kuwata, H., Nakatani, Y., Murakami, M., and Kudo, I. (1998) J. Biol. Chem. 273, 1738–1740
9. Bingham, C. O., Murakami, M., Fujishima, H., Hunt, J. E., Austen, K. F., and Arm, J. P. (1996) J. Biol. Chem. 271, 25936–25944
10. Murakami, M., Bingham, C. O., Matsumoto, R., Austen, K. F., and Arm, J. P. (1995) J. Immunol. 155, 4445–4453
11. Reddy, S. T., Winstead, M. V., Tischfeld, J. A., and Herschman, H. R. (1997) J. Biol. Chem. 272, 13595–13596
12. Reddy, S. T., and Herschman, H. R. (1997) J. Biol. Chem. 272, 3231–3237
13. Fujishima, H., Sánchez Mejía, R. O., Bingham, C. O., Lamm, B. K., Sapirstein, A., Bonventre, J. V., Austen, K. F., and Arm, J. P. (1996) Proc. Natl. Acad. Sci. U. S. A. 96, 4803–4808
14. Sawada, H., Murakami, M., Enomoto, A., Shimbara, S., and Kudo, I. (1999) Eur. J. Biochem. 263, 826–833
15. Glaser, K. B., Amnis, R., and Dennis, E. A. (1990) J. Biol. Chem. 265, 8658–8664
16. Balsinde, J., Balboa, M. A., Insel, P. A., and Dennis, E. A. (1997) Biochem. J. 321, 865–889
17. Balsinde, J., Shinohara, H., Lefkowitz, L. J., Johnson, C. A., Balboa, M. A., and Dennis, E. A. (1999) J. Biol. Chem. 274, 25967–25970
18. Balsinde, J., Fernández, B., Solís-Herruzo, J. A., and Diez, E. (1992) Biochim. Biophys. Acta 1136, 75–81
19. Barbour, S. E., and Dennis, E. A. (1993) J. Biol. Chem. 268, 21875–21882
20. Balboa, M. A., Balsinde, J., Jones, S. S., and Dennis, E. A. (1997) J. Biol. Chem. 272, 8576–8580
21. Balsinde, J., Balboa, M. A., and Dennis, E. A. (1997) J. Biol. Chem. 272, 29317–29321
22. Akiba, S., Mizunaga, S., Kume, K., Hayama, M., and Sato, T. (1999) J. Biol. Chem. 274, 19966–19972
23. Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 37, 911–917
24. Balsinde, J., and Dennis, E. A. (1996) Eur. J. Biochem. 235, 480–485
25. Lister, M. D., Glaser, K. B., Ulevitch, R. J., and Dennis, E. A. (1989) J. Biol.
26. Balsinde, J., Bianco, I. D., Ackermann, E. J., Conde-Friebbe, K., and Dennis, E. A. (1995) *Proc. Natl. Acad. Sci. U. S. A.* 92, 8527–8531
27. Balsinde, J., and Dennis, E. A. (1996) *J. Biol. Chem.* 271, 31937–31941
28. Dan, P., Dagan, A., Krinsky, M., Pruzanski, W., Vadas, P., and Yedgar, S. (1998) *Biochemistry* 37, 6199–6204
29. Balsinde, J., Balboa, M. A., Yedgar, S., and Dennis, E. A. (2000) *J. Biol. Chem.* 275, 4783–4786
30. Balboa, M. A., Balsinde, J., Winstead, M. V., Tischfield, J. A., and Dennis, E. A. (1996) *J. Biol. Chem.* 271, 32381–32384
31. Futaki, N., Takahashi, S., Yokoyama, M., Arai, I., Higuchi, S., and Otomo, S. (1994) *Prostaglandins* 47, 55–59
32. Balsinde, J., Barbour, S. E., Bianco, I. D., and Dennis, E. A. (1994) *Proc. Natl. Acad. Sci. U. S. A.* 91, 11060–11064
33. Balboa, M. A., Balsinde, J., Johnson, C. A., and Dennis, E. A. (1999) *J. Biol. Chem.* 274, 36764–36768
34. Bingham, C. O., Fijneman, R. J. A., Friend, D. S., Goddeau, R. P., Rogers, R. A., Austen, K. F., and Arn, J. P. (1999) *J. Biol. Chem.* 274, 31476–31484
35. Balsinde, J., and Dennis, E. A. (1997) *J. Biol. Chem.* 272, 16669–16672
36. Balsinde, J., and Dennis, E. A. (1997) *Adv. Exp. Med. Biol.* 407, 99–103
37. Baburina, I., and Jackowski, S. (1999) *J. Biol. Chem.* 274, 9400–9408
38. Alzola, E., Pérez-Etxebarria, A., Kabre, E., Fogarty, D. J., Métinou, M., Chaib, N., Macarulla, J. M., Matute, C., Dehaye, J. P., and Marino, A. (1998) *J. Biol. Chem.* 273, 30208–30217
39. Daniele, J. J., Fidelio, G. D., and Bianco, I. D. (1999) *Prostaglandins* 57, 341–350
40. Barbour, S. E., Kapur, A., and Deal, C. L. (1999) *Biochim. Biophys. Acta* 1439, 77–88
41. Ramanadham, S., Hsu, F. F., Behrer, A., Ma, Z., and Turk, J. (1999) *J. Biol. Chem.* 274, 13915–13927
Identification of a Third Pathway for Arachidonic Acid Mobilization and Prostaglandin Production in Activated P388D1 Macrophage-like Cells
Jesús Balsinde, María A. Balboa and Edward A. Dennis

J. Biol. Chem. 2000, 275:22544-22549.
doi: 10.1074/jbc.M910163199 originally published online May 15, 2000

Access the most updated version of this article at doi: 10.1074/jbc.M910163199

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

This article cites 41 references, 30 of which can be accessed free at http://www.jbc.org/content/275/29/22544.full.html#ref-list-1